<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03225248</url>
  </required_header>
  <id_info>
    <org_study_id>KUP-MSP5-301</org_study_id>
    <nct_id>NCT03225248</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia</brief_title>
  <official_title>Multi-center, Randomized, Active-Controlled, Double-Blind, Non-Inferiority, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia (MARS Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea United Pharm. Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea United Pharm. Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multi-center, randomized, active-controlled, double-blind, non-inferiority,
      phase III clinical trial evaluating efficacy and safety of once-daily mosapride
      (UI05MSP015CT) in patients with functional dyspepsia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with functional dyspepsia were randomly assigned (1:1) to receive either
      UI05MSP015CT (15 mg once daily before breakfast, study group) or mosapride (5 mg three times
      a day before each meal, control group) and corresponding placebo t.i.d. or q.d. for 4 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 5, 2014</start_date>
  <completion_date type="Actual">October 12, 2015</completion_date>
  <primary_completion_date type="Actual">September 5, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of symptom score of functional dyspepsia</measure>
    <time_frame>4weeks</time_frame>
    <description>Change of symptom score of functional dyspepsia was evaluated by symptom-specific questionnaire.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of symptom score of functional dyspepsia</measure>
    <time_frame>2weeks</time_frame>
    <description>Change of symptom score of functional dyspepsia was evaluated by symptom-specific questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General symptom improvement</measure>
    <time_frame>2weeks, 4weeks</time_frame>
    <description>Selecting: 'loss of symptom', 'apparent improvement', 'moderate improvement', 'no change', and 'deterioration'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NDI-K questionnaire</measure>
    <time_frame>4weeks</time_frame>
    <description>25 questions on five quality of life areas</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">143</enrollment>
  <condition>Functional Dyspepsia</condition>
  <arm_group>
    <arm_group_label>UI05MSP015CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UI05MSP015CT and Placebo of Gasmotin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gasmotin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo of UI05MSP015CT and Gasmotin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UI05MSP015CT</intervention_name>
    <description>UI05MSP015CT and Placebo of Gasmotin</description>
    <arm_group_label>UI05MSP015CT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gasmotin</intervention_name>
    <description>Placebo of UI05MSP015CT and Gasmotin</description>
    <arm_group_label>Gasmotin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt;19 years

          2. Diagnosis of functional dyspepsia meeting Rome III criteria

          3. At least three moderate or severe symptoms included in the Symptom Score

          4. No structural lesions of upper gastrointestinal tract

        Exclusion Criteria:

          1. History of dyspepsia unrelated to functional dyspepsia or diseases

          2. History of gastrointestinal surgery

          3. History of malignancy in the previous 5 years

          4. Psychiatric disorders including major depressive disorder and anxiety

          5. Liver cirrhosis or abnormal liver laboratory findings

          6. Advanced chronic kidney disease

          7. Uncontrolled hypertension

          8. Uncontrolled diabetes

          9. Pregnancy and lactation

         10. Recent history of taking medication affecting the gastrointestinal system
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2017</study_first_submitted>
  <study_first_submitted_qc>July 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>July 20, 2017</last_update_submitted>
  <last_update_submitted_qc>July 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
    <mesh_term>Gastritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

